Below is a list of abstracts presented at ECCO ....
they are limited to Erbitux / Avastin / Panitumumab
(this list maybe incomplete due to searching errors
on my part)
I am not trying to clutter this board and going forward
will just read ..... but there maybe useful information
here that others may want to talk to or highlight ....
Avastin
Avastin - Abstract 117: Novel therapeutic approaches: molecular targeted therapy
Message 21847949
Avastin - Abstract 1274: Impact of bevacizumab plus 5FU/LV with or without irinotecan on quality of life in patients with metastatic colorectal cancer
EDIT
The addition of BV to IFL significantly prolonged progression-free survival (PFS) by 71% and overall survival (OS) by 30% [Hurwitz et al. J Clin Oncol 2004;22:2335–42].
In a phase II study, 209 subjects were randomized to 5-FU/LV+placebo (105) or 5-FU/LV+BV (104); addition of BV to 5-FU/LV significantly prolonged PFS [Kabbinavar et al. J Clin Oncol 2005;23: epub ahead of print February 28]. Evaluating changes in quality of life (QOL) was a secondary objective in both studies.
Message 21847955
Avastin - Abstract 40: Systemic therapy and novel targeted therapies in renal cancer
Message 21847962
Avastin - Abstract 53: HPMA copolymer-TNP-470 (caplostatin) and Avastin show synergistic inhibition of human tumor growth in mice
EDIT
A potential explanation for the favorable combination would be that Avastin inhibits tumor growth by targeting VEGF while VEGF is only one of many angiogenesis stimulators.
TNP-470 which has the broadest spectrum of any known antiangiogenic/anti-cancer agent, may target multiple pathways.
Our data suggest that combining two non-toxic angiogenesis inhibitors can have increased synergistic anti-tumor effect and no toxicity.
The clinical translation of this novel combination is warranted.
Message 21847975
Avastin - Abstract 602: Preliminary safety of bevacizumab with first-line FOLFOX, CAPOX, FOLFIRI and Capecitabine for mCRC - First BEATrial
EDIT
In a phase III pivotal trial in patients (pts) with metastatic colorectal cancer (mCRC), bevacizumab (BEV, Avastin®) increased overall survival by 30% when added to first-line IFL chemotherapy (CT).
Message 21847978
Avastin - Abstract 629: Starting bevacizumab shortly after venous access device implantation appears not to increase wound healing/bleeding complications nor catheter related thromboses - preliminary results from First BEAT
Message 21847985
Avastin - Abstract 635: Arterial thromboembolic events in a pooled analysis of 5 randomized, controlled trials of bevacizumab with chemotherapy
EDIT
The addition of bevacizumab to chemotherapy is associated with an increased risk of arterial thromboembolic events in patients with metastatic carcinoma, especially those =65 years old with a prior history of arterial thromboembolic events.
Message 21847988
Avastin - Abstract 643: Clinical benefit of bevacizumab in responding and non-responding patients with metastatic colorectal cancer
EDIT
These analyses suggest that the magnitude of clinical benefit associated with bevacizumab treatment, as measured by HR for PFS and OS, is similar in mCRC, regardless of objective tumor response.
This response-independent survival benefit is a novel observation in mCRC, and has implications for endpoint selection in bevacizumab-based clinical trials and the routine clinical use of bevacizumab.
Data suggest that strategies of discontinuing bevacizumab in patients without an objective tumor response or at the time of maximal tumor response may compromise overall clinical benefit with respect to PFS and OS.
Message 21847994
Erbitux
Erbitux - Abstract 642: Cetuximab plus oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) for the epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer (mCRC) in the first-line setting: a phase II study
EDIT
Of the 62 patients enrolled, 52 (84%) had EGFR-expressing disease.
Among 42 evaluable patients, there was an objective response rate of 81% (34/42), with 4 complete (CR) and 30 partial responses (PR). The disease control rate (CR+PR+stable disease) was 98%.
The median duration of response (n = 31) was 330 days (10.9 months) and the median progression-free survival (PFS) was 12.3 months, with a 12-month PFS rate of 52%.
Message 21848004
Erbitux - Abstract 664: Cetuximab in combination with irinotecan/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFIRI) in the first-line treatment of metastatic colorectal cancer (mCRC)
EDIT
Cetuximab+FOLFIRI, incorporating high-dose 5-FU, is a feasible and active combination for the first-line treatment of EGFR-expressing mCRC.
45.2% of patients achieved an objective response.
The median survival was 23 months and 23.8% patients were able to undergo resection of initially unresectable metastases. Based on these results, a new phase III trial was started.
Message 21848008
Erbitux - Abstract 699: Cutaneous and non-cutaneous toxicity induced by biologic therapy with cetuximab (erbitux)
EDIT
Toxicity pattern induced by cetuximab is various in terms of type, organ involved and events' severity.
In our experience we have registered different types of cutaneous toxicities, generally spontaneously reversible after temporary interruption of therapy.
Finally, for the first time in literature, we have reported a characteristic ophthalmic toxicity (blepharitis) caused by cetuximab
Message 21848010
Erbitux - Abstract 702: Cetuximab and irinotecan/5-fluorouracil (5-FU)/folinic acid (FA) (AIO) is active and safe in the first-line treatment of metastatic colorectal cancer (mCRC) expressing the epidermal growth factor receptor (EGFR)
EDIT
Cetuximab plus weekly infusional 5-FU/FA (AIO) and irinotecan is safe and has demonstrated a promising overall response rate of 67% and median OS of 33 months.
A 5-FU dose of 1,500 mg/m2 in this combination is recommended for further studies in this setting.
Panitumumab
Panitumumab - Abstract 1123:
Panitumumab, a fully human antibody, combined with paclitaxel and carboplatin versus paclitaxel and carboplatin alone for first line advanced non-small cell lung cancer (NSCLC): a primary analysis
EDIT
Results from this phase 2 study indicate that panitumumab + PC is well tolerated with similar efficacy as PC alone in an unselected NSCLC population.
Retrospective assessment of tumors for biomarkers may define subpopulations more likely to benefit from panitumumab.
Clinical studies of panitumumab in NSCLC are ongoing with other novel combinations of targeted agents.
Message 21852234
Panitumumab - Abstract 653: First line therapy of Panitumumab, a fully human antibody, in combination with FOLFIRI for the treatment (txt) of metastatic colorectal cancer (mCRC)
EDIT
Eight (33%) pts had a partial response, 11 (46%) had stable disease, and 3 (13%) had PD; 2 (8%) pts did not have an evaluable response.
From this small study, panitumumab in combination with FOLFIRI as first line therapy appears to be well tolerated. These findings warrant further investigation in a larger trial.
Message 21852253
Below is a link from which you can do your own
searches
ex2.excerptamedica.com |
